Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranexa Angina Reduction Enough For Restricted Indication, CVT Says

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

A mean weekly reduction of 0.4 angina attacks seen in the ERICA study with CV Therapeutics' Ranexa (ranolazine) is adequate for approval, the company said, despite being less than half the expected decrease

You may also be interested in...



Ranexa MERLIN study complete

CV Therapeutics expects top-line data from its MERLIN study of Ranexa (ranolazine) in the first quarter of 2007. The firm announced Sept. 26 that MERLIN (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes) is complete and will soon move to the close-out phase. MERLIN was designed under a special protocol assessment with FDA; the agreement stipulates that if the primary endpoint of time to first occurrence of any element of a composite endpoint is met, Ranexa could potentially be approved for treatment of ACS and secondary prevention. CVT has also said it believes MERLIN would support a labeling expansion to first-line angina (1Pharmaceutical Approvals Monthly May 2005, p. 10)...

CVT Ranexa complete response

CV Therapeutics submits its "complete response" to an October 2003 "approvable" letter for its angina treatment Ranexa (ranolazine) July 27. The amendment seeks a narrowed indication based on the FDA-requested ERICA (Evaluation of Ranolazine in Chronic Angina) study of patients refractory to Pfizer's Norvasc (amlodipine), which compared the partial fatty acid oxidation inhibitor plus the maximum labeled dose (10 mg) of Norvasc to Norvasc alone. CVT has said that the 0.4 attack/week reduction seen in ERICA was sufficient for an indication for a restricted population, despite being less than half the projected 1.0-1.2 reduction (1Pharmaceutical Approvals Monthly May 2005, p. 10). Assuming a six-month review of the amendment, Ranexa could launch in the first half of 2006...

Ranexa Could Be First Approval For First-Line Angina With MERLIN Trial

CV Therapeutics’ Ranexa could receive the first approval for first-line treatment of chronic angina if a new outcomes trial does not detect a trend towards death or arrhythmia, the company said.

Topics

UsernamePublicRestriction

Register

PS002907

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel